secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2024-11-22T23:59:59+00:00
Accession:  0000950170-24-129971
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo highlights bispecific pipeline; first AML patient shows 90% blast reduction
--------------------------------------------------------------------------------

- First patient in Phase 1b/2 RAINIER trial for mipletamig achieved 90% leukemic blast reduction within 30 days.
- ALG.APV-527 Phase 1 data: 9 of 16 evaluable patients (56%) achieved stable disease; safety and tolerability positive.
- Preclinical candidates APVO711, APVO603, APVO442 target PD-L1/CD40, 4-1BB/OX40, PSMA/CD3 respectively.
- Company plans to add another targeted asset to pipeline in near-term but provides no details.
- No financial updates or guidance provided; no leadership or corporate changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024129971/0000950170-24-129971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017024129971/apvo-20241122.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer